The value of adjuvant treatment in young women with breast cancer

Drugs

Volumn 62, Issue 1, 2002, Pages 1-11

  Clive, S ^a   Dixon, J M ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN AGONIST; METHOTREXATE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

APPETITE DISORDER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARDIOTOXICITY; FATIGUE; FEMALE; FERTILITY; HOT FLUSH; HUMAN; LEUKOPENIA; NAUSEA AND VOMITING; OVARY CYST; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SWEATING; TASTE DISORDER; VAGINA DISEASE;

EID: 0036181498     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262010-00001     Document Type: Review

References (80)

1. Hereditary breast cancer
2. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer
3. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases
4. Radiation and other environmental exposures and breast cancer
5. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment
6. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood
7. Prognostic significance of young age in breast cancer
8. Factors influencing the effect of age on prognosis in breast cancer: Population based study
9. Age as prognostic factor in premenopausal breast carcinoma
10. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer
11. C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: Immunohistochemical analysis and clinicopathologic correlation
12. Breast carcinomas occurring in young women (<35 years) are different
13. C-erbB-2 overexpression and survival in early onset breast cancer
14. Stage 0 to stage III breast cancer in young women
15. Early-onset breast cancer: Histopathological and prognostic considerations
16. The influence of young age on outcome in early stage breast cancer
17. The national cancer database report on breast carcinoma characteristics and outcome in relation to age
18. Younger women with breast carcinoma have a poorer prognosis than older women
19. Prognostic factor
20. Clinical trials of management of breast cancer
21. Polychemotherapy for early breast cancer: Overview of the randomised trials
22. Meeting highlights: International consensus panel on the treatment of primary breast cancer
23. Should all younger patients with breast cancer be offered adjuvant cytotoxic chemotherapy?
24. The prognosis of small primary breast cancers
25. Tamoxifen for early breast cancer: An overview of randomised trials
26. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
27. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
28. Adjuvant cyclophosphamide, methotrexate and flourouracil versus flourouracil, epirubicin, cyclophosphamide chemotherapy in premenopausal women with axillary node positive operable breast cancer: Results of a randomised trial
29. Randomised trial of intensive cyclophosphamide, epirubicin and 5 flourouracil chemotherapy compared with cyclophosphamide, methotrexate and flourouracil in premenopausal women with node positive breast cancer
30. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than 3 positive nodes: 10 year results
31. Improved disease-free survival and overall survival from the addition of sequential paclitaxel in the adjuvant chemotherapy of patients with node-positive primary breast cancer
32. Role of paclitaxel in adjuvant therapy of operable breast cancer: Preliminary results of prospective randomized clinical trial
33. The taxanes: An update
34. North American adjuvant breast cancer trials
35. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian breast group 9401 study
36. A prospective randomised comparison of 2 doses of combination alkylating agents (AA) as consolidation after CAF in high risk primary breast cancer involving 10 or more axillary lymph nodes: Preliminary results of CALGB9082/SWOG91104/NCICMA- 13
37. Overall survival (OS) advantage to simultaneous chemotherapy plus humanised anti HER2 monoclonal antibody Herceptin in HER2: Overexpressing metastatic breast cancer
38. Herceptin in the adjuvant setting: Phase III trials begin
39. Current and planned clinical trials with trastuzumab
40. Scalp cooling has no place in the prevention of alopecia in adjuvant chemotherapy for breast cancer
41. Quality of life, survivorship, and psychosocial adjustment of young women with breast cancer after breast-conserving surgery and radiation therapy
42. Quality of life after adjuvant chemotherapy for breast cancer
43. Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy
44. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: An eastern cooperative oncology group study
45. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: Role of cardiac risk factors
46. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants
47. Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer
48. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and flurouracil in positve-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the national surgical adjuvant breast and bowel project B-15
49. Pregnancy after breast cancer: From psychosocial issues through conception
50. Breast cancer in young women: Effect of chemotherapy on ovarian function, fertility, and birth defects
51. Prospects for fertility after cancer chemotherapy
52. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
53. The thrombophilic state induced by therapeutic agents in the cancer patient
54. Tamoxifen and risk of idiopathic venous thromboembolism
55. Radiotherapy related lung fibrosis enhanced by tamoxifen
56. Her2 over-expression predicts adjuvant tamoxifen (TAM) failure for early breast cancer (EBC): Complete data at 20 yr of the Naples GUN randomized trial
57. Prolonged follow-up of the Swedish randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer and relationships to hormone receptor and ErbB2 levels
58. A metanalysis of the interaction between Her2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC)
59. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and ER positive tumours
60. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the national surgical adjuvant breast and bowel project B-14 randomised trial
61. Post chemotherapy adjuvant tamoxifen beyond 5 years in patients with lymph node positive breast cancer
62. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer
63. Tamoxifen: The treatment of choice. Why look for alternatives?
64. Update of endocrine therapy for breast carcinoma
65. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the national surgical adjuvant breast and bowel project (NSABP) B-14
66. Clinical trials of management of breast cancer
67. Anti-atherogenic effect of adjuvant anti-oestrogens
68. Hormonal therapy of breast cancer
69. Ovarian ablation in early breast cancer: Overview of randomised trials
70. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
71. Complete hormonal blockade versus chemotherapy in premenopausal early-stage breast cancer patients (pts) with positive hormone-receptor (HR+) and 1-3 node-positive (N+) tumor: Results of the FASG 06 trial
72. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen recep-tor-positive pre-/perimenopausal breast cancer patients: Results of the Italian breast cancer adjuvant study group 02 randomized trial
73. Current and future directions in medical therapy for breast carcinoma
74. Combination goserelin and tamoxifen is more effective than CMF in premenopausal patients with hormone responsive tumors in a multicenter trial of the Austrian breast cancer study group
75. Effect of chemohormonal therapy in premenopausal node positive receptor positive breast cancer: An eastern cooperative oncology group phase III intergroup trial (E5188, INT-0101)
76. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomized trial by the cancer research campaign (CRC) breast cancer trials group, the Stockholm breast cancer study group, the south-east Sweden breast cancer group and the gruppa interdisciplinara valurazione interventl in oncologia (GIVIO)
77. Post-mastectomy radiotherapy: Recommended standards
78. Does locoregional radiation therapy improve survival in breast cancer: A meta-analysis
79. Adjuvant radiotherapy for breast cancer significantly improves overall survival: The missing link
80. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: And overview of the randomised trials